Prostate cancer in deceased organ donors: A review

Doerfler, A.; Tillou, X.; Gal, S. Le; Desmonts, A.; Orczyk, Clément; Bensadoun, H.

doi:10.1016/j.trre.2013.10.003

Cited by 15 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 More recent studies, however, have indicated that careful selection of donors with less invasive cancers has since reduced the overall risk of donor-derived cancer to an estimated 0.06%. 10,11 Malignancy subtype and cancer-free period are additional considerations in donor selection criteria. Most malignancies in this analysis were skin and CNS cancers, followed by genitourinary and other cancers, which aligns with previous research findings.…”

Section: Discussionmentioning

confidence: 99%

“…The particular risk for hearts has been documented in a case report showing donor‐derived metastatic prostate cancer in a heart transplant recipient . More recent studies, however, have indicated that careful selection of donors with less invasive cancers has since reduced the overall risk of donor‐derived cancer to an estimated 0.06% …”

Section: Discussionmentioning

confidence: 99%

“…The US Donor Transmitted Assessment Committee and Council of Europe have provided scaled recommendations with regard to donor malignancies but permit autonomous decision making with regard to transplant appropriateness . However, in the absence of a national analysis of outcomes specific to heart transplantation, the true risk for donor transmission of malignancy remains uncharacterized . Current selection guidelines for heart donors do not specify how to proceed with a donor history of malignancy .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Donor history of malignancy: A limited risk for heart transplant recipients

Rudasill

Iyengar

Sanaiha

et al. 2020

Clinical Transplantation

View full text Add to dashboard Cite

Organ donor contraindications are frequently reassessed for impact on recipient outcomes in attempt to meet demand for transplantation. This study retrospectively analyzed the United Network for Organ Sharing (UNOS) registry for adult heart transplants from 1987 to September 2016 to characterize the impact of donor malignancy history in heart transplantation. Kaplan‐Meier estimates illustrated 10‐year survival. Propensity score matching was utilized for 1:1 matching of donors with and without history of malignancy, and Cox proportional hazards and logistic regressions were used to analyze the matched population. Of 38 781 heart transplants, 622 (1.6%) had a donor history of malignancy. Cox regressions demonstrated that donor malignancy predicted increased 10‐year mortality (HR = 1.16 [1.01‐1.33]), but this difference did not persist when conditioned upon 1 year post‐transplant survival (log‐rank = 0.643). Cox regressions of the propensity score‐matched population (455 pairs) found no association between donor malignancy and 10‐year mortality (HR = 1.02 [0.84‐1.24]). Older age and higher rates of hypertension were observed in donors with a history of malignancy whose recipients died within the first year post‐transplant. Therefore, increased recipient mortality is likely due to donor characteristics beyond malignancy, creating the potential for expanded donor selection.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Donor history of malignancy: A limited risk for heart transplant recipients

Rudasill

Iyengar

Sanaiha

et al. 2020

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…If PSA level is >10ng/ml, the risk of metastatic lymph nodes remains less than 20% for clinical stage T1 and T2a whatever Gleason score, but reaches over 20% for T2b (Gleason score 3+4) and 40% for T2c with Gleason score 8 to 10. 31,35 PSA level is up to 20 ng/ml for tumours that are T2b with Gleason score 6, have a positive lymph node risk of 6%. If PSA level is over 20 ng/ml, the positive lymph node risk is over 20% for T2b with Gleason score over 9 or for T3 with Gleason score over 7.…”

Section: Discussionmentioning

confidence: 99%

“…However practically this is not always available. 11,32,33,35 Micro metastatic prostate disease, in pelvic lymph nodes or blood may be missed by routine microscopic examination and so may be another consideration to take into account when discussing possible donors. 33 However there seems to be no significant difference in prognostic outcomes between patients diagnosed with histopathology sections and those diagnosed with micro metastases.…”

Section: Discussionmentioning

confidence: 99%

Renal donors with prostate cancer, no longer a reason to decline

Dholakia

Johns

Muirhead

et al. 2016

Transplantation Reviews

View full text Add to dashboard Cite

Urologische Nachsorge und Entwicklung von Malignomen nach Nierentransplantation

Giessing

2015

Urologe

View full text Add to dashboard Cite

Urological evaluation following RT must ensure correct urine transport and voiding function. Transplant ureter strictures, relevant ureteral reflux and voiding dysfuntion (e.g., neurologic dysfunction, benign prostate hypeplasia) must be excluded or treated. Urinary tract infection (UTI), which can be life threatening in the immunosuppressed transplant recipient, must be diagnosed and treated consequently and for an adequate period of time. Prophylaxis of UTIs is indicated in patients with recurrent symptomatic UTI as well as in the initial 6 months following renal transplantation. Asymptomatic bacteriuria must not necessarily be treated. The incidence of urological malignancies like renal cell carcinoma, urothelial cancer of the bladder, and penile carcinoma is increased following RT, while the incidence of prostate and testis cancer is the same as in the nontransplant population. Surgical and nonsurgical treatment options do not differ from the normal population. Adaptation, cessation, or switching of the immunosuppressive regimen in case of urologic malignancy must be decided on the individual recipient basis.

show abstract

Prostate cancer in deceased organ donors: A review

Cited by 15 publications

References 26 publications

Donor history of malignancy: A limited risk for heart transplant recipients

Donor history of malignancy: A limited risk for heart transplant recipients

Renal donors with prostate cancer, no longer a reason to decline

Urologische Nachsorge und Entwicklung von Malignomen nach Nierentransplantation

Contact Info

Product

Resources

About